190
Views
5
CrossRef citations to date
0
Altmetric
PCOS

Salusins, newly identified regulators of hemodynamics and mitogenesis, increase in polycystic ovarian syndrome

, , , , , , , & show all
Pages 83-86 | Received 22 Sep 2011, Accepted 29 May 2012, Published online: 24 Jul 2012

References

  • Celik O, Sahin I, Celik N, Hascalik S, Keskin L, Ozcan H, Uckan A, Kosar F. (2007). Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Hum Reprod, 22, 2992–2998.
  • Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C, Cummings MH. (2005). Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol, 58, 151–154.
  • Birdsall MA, Farquhar CM, White HD. (1997). Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med, 126, 32–35.
  • Blake GJ, Ridker PM. (2002). Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med, 252, 283–294.
  • Carmina E, Lobo RA. (1999). Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab, 84, 1897–1899.
  • Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. (2000). Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod, 15, 785–789.
  • Cussons AJ, Stuckey BG, Watts GF. (2006). Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis, 185, 227–239.
  • de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. (2011). PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update, 17, 495–500.
  • Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, Hirata Y. (2003). Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med, 9, 1166–1172.
  • Watanabe T, Nishio K, Kanome T, Matsuyama TA, Koba S, Sakai T, Sato K, Hongo S, Nose K, Ota H, Kobayashi Y, Katagiri T, Shichiri M, Miyazaki A. (2008). Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis. Circulation, 117, 638–648.
  • Watanabe T, Suguro T, Sato K, Koyama T, Nagashima M, Kodate S, Hirano T, Adachi M, Shichiri M, Miyazaki A. (2008). Serum salusin-α levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res, 31, 463–468.
  • Rajendran S, Willoughby SR, Chan WP, Liberts EA, Heresztyn T, Saha M, Marber MS, Norman RJ, Horowitz JD. (2009). Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis, 204, 509–514.
  • Trakakis E, Balanika A, Baltas C, Loghis C, Simeonidis G, Vaggopoulos V, Papakonstantinou O, Gouliamos A, Salamalekis G, Kassanos D. (2008). Hemodynamic alterations and wall properties in large arteries of young, normotensive, and non-obese women with polycystic ovary syndrome. J Endocrinol Invest, 31, 1001–1007.
  • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 81, 19–25.
  • Friedewald WT, Levy RI, Fredrickson DS. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18, 499–502.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985). Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412–419.
  • Celik O, Celik N, Hascalik S, Sahin I, Aydin S, Ozerol E. (2011). An appraisal of serum preptin levels in PCOS. Fertil Steril, 95, 314–316.
  • Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. (1998). Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol, 51, 415–422.
  • Wu FC, von Eckardstein A. (2003). Androgens and coronary artery disease. Endocr Rev, 24, 183–217.
  • Türkçüoglu I, Kafkasli A, Meydanli MM, Ozyalin F, Taskapan C. (2011). Independent predictors of cardiovascular risk in polycystic ovarian syndrome. Gynecol Endocrinol, 27, 915–919.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.